Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi

Running, not enrolling · Phase 3

Conditions studied: Spinal Muscular Atrophy Type I, Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type III, SMA

In brief

This is a long-term follow-up safety and efficacy study of participants in clinical trials for spinal muscular atrophy (SMA) who were treated with onasemnogene abeparvovec-xioi. Participants will roll over from their respective previous (parent) study into this long-term study for continuous monitoring of safety as well as monitoring of continued efficacy and durability of response to onasemnogene abeparvovec-xioi treatment.

Key facts

Study ID
NCT04042025
Run by
Novartis Gene Therapies
People needed
85
Starts
2020-02-10
Expected to finish
2035-12-31
Last updated by the study team
2025-04-25

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.